The Evidence Here is exactly what the SELECT trial found: 17,604 participants enrolled, all with established cardiovascular disease, BMI of 27 or greater, and no diabetes Primary MACE event rate: 6.5 percent in the semaglutide group versus 8.0 percent in the placebo group Hazard ratio of 0.80 means a 20 percent relative reduction in the risk of heart attack, stroke, or cardiovascular death 95 percent confidence interval: 0.72 to 0.90, meaning the true effect falls within that range with high certainty P value less than 0.001, which is statistically decisive Mean follow-up: 39.8 months Mean weight loss with semaglutide: 9.4 percent of body weight Serious adverse events leading to discontinuation: 16.6 percent in the semaglutide group versus 8.2 percent in the placebo group That last number is a bit concerning
Peptides are naturally fragile
Option 1: Stay on the Max Dose for Longer One approach for patients who reach weight loss plateaus on the maximum weekly dose of GLP-1s is to simply give it more time
Official Safety Data and Male Sexual Health FDAapproved labels outline many potential adverse reactions but do not include genital enlargement as a labeled or expected effect in clinical trials
The good news is that there are clear patternsand once you understand how insurers make these decisions, it becomes much easier to navigate your options
provider who knows your name and adjusts your plan as you go
